editorial comments about certain data items. The other agencies published a separate Federal Register notice on June 19, 2006 (71 FR 35325) and will each separately submit their SAR information collection to OMB.
Several commenters suggested that the agencies provide a test site for filing electronic submissions. Due to time constraints, FinCEN is unable to provide a test site; however, respondents will have a six-month transition period before being required to use the revised reporting form for submitting data.
Two commenters stated that the overall burden estimate appeared to be low even though it was increased from thirty minutes to one hour. One commenter specifically noted that the burden estimate did not account for regulatory compliance, fraud detection, and mitigation. While important, these regulatory requirements are outside the scope of the burden calculation required by the Paperwork Reduction Act. The agencies, however, continue to welcome comments from the industry and would reevaluate and make adjustments to the burden, as appropriate.
Several commenters expressed concern over the new format of the reporting form and whether it would cause important information to be omitted by respondents. The agencies rearranged data items on the reporting form, per law enforcement request, to improve the usefulness of the data. Also, additional clarifications were included in the instructions to provide respondents with better guidance on how to submit the revised data. 1. That Ms. Zhao darkened with a marking device the thioredoxin (Trx) band of Lanes 1 and 2 on the autoradiographic film that was to become part of Figure 9 of the manuscript.
2. That Ms. Zhao (a) falsified this same original film of the western blot by darkening Lanes 1, 2, 4, and 5 with a marking device at the origin of the gel and (b) further falsified Figure 9 of the Cancer Research manuscript by claiming falsely that these marked bands were thioredoxin reductase (TR) untreated and with mismatch oligodeoxynucleotide in the presence and absence of tumor necrosis factor alpha.
3. That Ms. Zhao falsified the glutathione reductase (GR) activity data in either Figure 4 or Figure 9 of the Cancer Research manuscript (the data are identical but stated to be from entirely different experimental conditions).
4. That Ms. Zhao falsified the actin data in either Figure 4 or Figure 9 of the Cancer Research manuscript or in the experiments simultaneously using Prx III-As and Phospholipid hydroperoxide glutathione peroxidase-As reported in slide presentations (the actin data are identical under 3 entirely different experimental conditions).
5. That Ms. Zhao falsified the manganese superoxide dismutase (MnSOD) data in either Figure 1A or Figure 4 of the Cancer Research manuscript (these MnSOD data are identical while being clearly described as coming from different experiments).
6. That Ms. Zhao falsified the MnSOD data in Figure 2 of the Cancer Research manuscript by enhancing with a marking device Lanes 6 and 7, mismatch and antisense Prx oligos at 3 days of incubation (unmarked, Prx IIIAs decreased the expression of MnSOD).
Ms. Zhao has entered into a Voluntary Exclusion Agreement in which she has voluntarily agreed, for a period of three (3) years, beginning on June 3, 2006:
(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in the debarment regulations at 45 CFR part 76;
(2) To exclude herself from serving in any advisory capacity to PHS including, but not limited, to service on any PHS advisory committee, board, and/or peer review committee, or as consultant. Copies of the proposed collection plans, data collection instruments, and specific details on the estimated burden can be obtained from AHRQ's Reports Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ, Reports Clearance Officer, (301) 427-1477. To address customer requirements and to evaluate current and future AHRQ products and services, the Eisenberg Center must periodically determine how well the Eisenberg Center products and services are meeting customer's' current and anticipated needs. Work conducted under this clearance will improve the products and services the Center develops for AHRQ for a three year period. The health care environment changes rapidly and requires a quick response from AHRQ to provide appropriately refined products and services. A generic clearance for this work will facilitate AHRQ's timely response to customers' needs.
Methods of Collection
Participation in survey testing will be fully voluntary and non-participation will have not affect on eligibility for, or receipt of, future AHRQ health services research support, on future opportunities to participate in research or to obtain informative research results. Specific estimation procedures, when used, will be described when we notify OMB as to actual studies conducted under the clearance.
